Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants

Hentzien, Maxime; Owen, Andrew; Strub-Wourgaft, Nathalie; Pérez-Casas, Carmen; Trøseid, Marius; Calmy, Alexandra

doi:10.3389/fmicb.2022.998287

Scientific article

English

Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants

ContributorsHentzien, Maxime; Owen, Andrew; Strub-Wourgaft, Nathalie; Pérez-Casas, Carmen; Trøseid, Marius; Calmy, Alexandra

Published inFrontiers in microbiology, vol. 13, 998287

Publication date2022-10-12

First online date2022-10-12

Keywords

COVID-19
Direct-acting antivirals
Immunocompromised
Monoclonal antibodies
Omicron
Resistance
Variant emergence
Variants

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

VIH/SIDA (930)

Citation (ISO format)

HENTZIEN, Maxime et al. Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants. In: Frontiers in microbiology, 2022, vol. 13, p. 998287. doi: 10.3389/fmicb.2022.998287

Article (Published version)

CC BY-4.0

Identifiers

PID : unige:173141
DOI : 10.3389/fmicb.2022.998287
PMID : 36312942
PMCID : PMC9597299

Additional URL for this publicationhttps://www.frontiersin.org/articles/10.3389/fmicb.2022.998287/full

Journal ISSN1664-302X

262views

88downloads

Creation07/02/2023 08:48:24

First validation17/11/2023 18:49:57

Update17/11/2023 18:49:57

Status update17/11/2023 18:49:57

Last indexation01/11/2024 06:45:21

Archive ouverte UNIGE

Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants

Technical informations